The former chief executive of a biopharmaceutical company used insider information about contamination in a COVID-19 vaccine to make more than $10 million in trades, the New York Attorney General’s ...

A former biotech CEO pocketed more than $10 million by selling company stock after learning of serious COVID-19 vaccine contamination problems — before those issues were made public, according to a ...

Emergent BioSolutions Inc. (NYSE: EBS) stock rose in Friday premarket trading. On Thursday, New York Attorney General Letitia James sued former chief executive Robert G. Kramer over alleged insider ...

New York Attorney General Letitia James filed suit against the former head of Emergent BioSolutions EBS-1.60%decrease; red down pointing triangle, accusing him of insider trading for selling his ...

NEW YORK, Jan 15 (Reuters) - A former chief executive of Emergent BioSolutions was charged on Thursday with insider trading by New York Attorney General Letitia James for allegedly selling the ...

Two years ago, Emergent BioSolutions came to a settlement with shareholders, agreeing to pay $40 million to resolve allegations of wrongdoing by company executives, which included insider trading ...

New York Attorney General Letitia James filed suit against the former head of Emergent BioSolutions, accusing him of insider trading for selling his shares in the company before disclosing ...

The New York attorney general’s office has filed suit against the former CEO of Emergent Biosolutions Inc., alleging insider trading, while at the same time announcing a settlement with the company, ...